Drug Profile
Research programme: muscarinic M3 receptor antagonists - Novartis
Latest Information Update: 13 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 13 Jul 2010 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Singapore (Inhalation)
- 13 Jul 2010 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Switzerland (Inhalation)
- 13 Jul 2010 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)